November 11, 2014 (Shareholders Foundation) - An investigation was announced on behalf of investors, who SOLD any NYSE:AGN shares between February 25, 2014 and April 21, 2014, concerning potential violations of Federal Securities Laws for having sold their Allergan shares between February and April 2014 at a potentially depressed stock price.

The investigation by a law firm concerns possible claims on behalf of persons who sold Allergan common stock between February 25, 2014 and April 21, 2014 without the benefit of the information that Valeant Pharmaceuticals International, Inc. (Valeant) and Pershing Square Capital Management, L.P. (Pershing Square) proposed to acquire Allergan shares at a significant premium. According to the investigation this information was revealed to the investing public on April 22, 2014, when Allergan announced the receipt of the acquisition proposal made by Valeant and Pershing Square and sellers of Allergan shares between February 25, 2014 and April 21, 2014 may be able to recover damages against Valeant and Pershing Square.

After the April 2014 announcement, Allergans stock price soared due to the disclosure of the interest of Valeant and Pershing Square in acquiring Allergan.

The investigation says that had Allergan shareholders known of Valeant and Pershing Squares plans, they would not have sold their Allergan stock between February 25, 2014 and April 21, 2014 and that both Valeant and Pershing Square profited handsomely from buying Allergan stock between February 25, 2014 and April 21, 2014 with the information then unavailable to the public concerning their forthcoming take-over proposal.
Indeed, between February 25, 2014 and April 21, 2014, Allergan stock traded below $142.00 per share and by comparison, Allergan stock has been trading at prices between $151.92 and $213.37 since April 22, 2014, when the proposed acquisition was announced.